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Background: Infection with Epstein-Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two
ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and
adolescent, which causes infectious mononucleosis (IM) in ~25% cases. The determinants of whether the infection
causes IM remain uncertain. We aimed to evaluate seasonality and temporal trends in IM.
Methods: Data from all Monospot tests, used as a marker for IM, were collected from the Grampian population
over 16 years.
Results: Positive Monospot test results peaked at 17 years in females and 19 in males. Females had 16% more
diagnoses, although 55% more tests. IM was ~38% more common in winter than summer. The annual rate of
positive tests decreased progressively over the study period, from 174/100 000 (95% CI 171–178) in 1997 to 67/100
000 (95% CI 65–69) in 2012.
Conclusions: IM appears to be decreasing in incidence, which may be caused by changing environmental
influences on immune systems. One such factor may be exposure to sunlight.
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The principle that diseases caused by infectious agents
arise from complex interactions between host and patho-
gen is exemplified by the constellation of symptoms and
complications that can arise from Epstein–Barr virus
(EBV). EBV is a human-specific herpes virus that infects
90-95% of adults [1] and has co-evolved with its host. In
non-industrialised countries, over 90% of primary infec-
tions occur in the first few years of life [2] and cause no
distinct symptoms. In industrialised countries, probably
because of higher standards of hygiene [3], 25-40% of
children escape primary infection [4]. Instead, infection
is delayed until adolescence or early adulthood, when
about 25% of infections cause infectious mononucleosis* Correspondence: e.visser@abdn.ac.uk
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reproduction in any medium, provided the or(IM) [5], which is variable in its presentation but com-
monly manifests as pharyngitis, fever and lymphaden-
opathy [1]. The immune response in IM is unusually
strong [6] and is thought to underlie the severity of the
disease.
After primary infection, the virus establishes a latent
infection in memory B-lymphocytes [7]. The virus has
transforming properties and may later cause serious
diseases such as Hodgkin lymphoma, several forms of
non-Hodgkin lymphoma or nasopharyngeal carcinoma
[8]. It has also been associated with chronic fatigue
syndromes and an increased risk for immune mediated
diseases such as multiple sclerosis (MS) in later life,
although causality is uncertain [9-12].
Although genetic influences encoded within both class I
and II major histocompatibility complex loci and mode of
infection are thought to determine whether individuals de-
velop IM [13], why the immune response to this infectioustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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poorly understood. Age dependent processes such as
variation in host antibodies and pre-existing infection
resulting in cross-reactions in T-cell populations may
play important roles [14,15].
In addition to age, there are numerous environmental
influences on immune responses. Increases in the inci-
dences of allergic and autoimmune diseases over the last
50 years are well described [16,17]. The reasons for these
increases are uncertain, although declines in infectious
diseases have been suggested. One environmental factor
that has attracted much recent attention is vitamin D.
Vitamin D levels are determined by both oral intake and
exposure to sunlight, so that vitamin D levels are higher
in summer than winter. Seasonality in both infectious
and non-infectious diseases has been described as far back
as Hippocrates (~380 BC) [18]. Presentation of several
immune mediated diseases is higher in spring and in
those who were born in spring [18-20]. Receptors for
vitamin D are widely expressed in the immune system
[21] and vitamin D has been shown to promote immune
tolerance in dendritic antigen presenting cells [22].
We postulated that IM might be the result of a relative
deficiency in immune tolerance. If infection occurs in
the winter months, when vitamin D levels are lower,
there might be a greater risk for developing infectious
complications [23], especially IM [24]. In an epidemio-
logical study of IM conducted in the 1960s in North-East
Scotland no seasonal variation was demonstrated and the
incidence was noted to be increasing, which may have
reflected increasing awareness [25]. We performed a more
extensive epidemiological survey of IM over a 16 year
period, specifically looking for evidence of seasonality and
changing rates of IM.
Methods
Tests
Data from patients who had a heterophile antibody test
(Monogen rapid latex particle agglutination test, Mono-
spot test) for acute EBV infection performed during the
period from 1997–2012 were collected anonymously.
The same test kit was used throughout the study period.
The Monospot test sensitivity and specificity for acute
EBV infection are both ~93% [26]. Serological EBV test
data (EBV viral capsid antigen IgM test) for the period
2000 to 2012 were also gathered anonymously. The im-
munology laboratory moved from a combination of EIA
(Enzyme Immuno-Assay) and immunofluorescence used
up to 2012, to using EIA only from 2012 onwards.
Study population
Clinical information on the onset of symptoms, indication
for testing and demographic information on permanent or
temporary residency in the area were not available. Age,gender, date of testing and results of tests were collected
retrospectively from the haematology laboratory of
Aberdeen Royal Infirmary, which is the sole provider of
diagnostic services for the population of 570 526 in the
Grampian area (latitude 56.837° N to 57.41°N) [27].
Tests received from both primary and secondary care
were included. The Grampian area includes Aberdeen
city, a number of smaller towns and large farming com-
munities. There are a number of secondary and tertiary
educational facilities that attract students from the UK
and worldwide. According to the 2001 census, 6% of the
population in this area were not native to Scotland and
that figure recorded in 2011 is now 16% [28]. An en-
quiry to the North of Scotland Research ethics commit-
tee revealed that no ethics permission was needed for
this project.
Statistical analysis
Annual age-gender specific rates of positive Monospot
tests were calculated using the relevant Grampian popu-
lation as published by the Information Services Division
(ISD) of Scotland [27] and then standardised against the
June 2009 Scottish population [29]. Confidence intervals
were calculated assuming a Poisson distribution. Micro-
soft Excel and StatsDirect were used to calculate trends,
rates and confidence intervals. The numbers of sero-
logical tests for acute EBV infection were compared with
Monospot tests to account for any change in diagnostic
methods for IM. Median ages for males and females and
interquartile ranges (IQR) were calculated and the differ-
ence in ages for males and females was analysed using a
Mann–Whitney U non-parametric test.
Data on all tests and positive results were tested for
seasonal trends using modified Roger’s and Edwards’
tests. The number of tests were plotted by month and a
sinusoidal curve of best fit was included [30,31]. These
analyses were repeated for different age groups and gender.
The peak months, amplitudes (with crude 95% confidence
intervals [CI]) and significance levels were calculated from
the sinusoidal curves.
Role of funding source
The funding sources had no role in the study design,
data collection, analysis, interpretation or writing of the
report. The corresponding author had final responsibility
for the decision to submit for publication.
Results
General population data for Grampian were collected
bi-annually before 2001 and quarterly thereafter and
showed no evidence of seasonal variation and change
over time. The original database comprised IM test re-
sults of 62228 requests from January 1997 to December
2012 (See Additional file 1). We first plotted the
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Figure 1 Positive Monospot tests from 1997 to 2012. Number of tests performed per year shown by grey line and right hand scale.
Age-gender standardised rate shown by black line and left hand scale.
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Figure 2 Total Monospot and EBV specific antibody tests
performed 1997 to 2012.
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A substantial downward trend was apparent, with the
number of cases approximately halving over the study
period (Figure 1). As the result was unexpected, we
tested whether several confounding factors might
explain the decrease. Initially, we tested for changes in
the denominator population. Age-gender standardised
rates of positive Monospot tests showed the same trend
(Figure 1). The annual rates of positive IM tests declined
from 174/100 000 (95% CI 171–178) in 1997 to 67/100
000 (95% CI 65–69) in 2012 (See Additional file 1 for data
and populations).
We also considered whether tests for IM investigating
EBV specific antibodies performed by the virology labora-
tory might have been increasingly favoured above the
Monospot tests performed by the haematology laboratory.
Serological data were available from 2000 onwards. There
was an increase in test requests for EBV specific antibodies
(n = 806 in 2000 to n = 981 in 2012) (Figure 2), but this
could not account for most of the decrease in Monospot
requests.
Our third consideration was that ‘diagnostic fashion’
might have changed over the study period. For instance,
patients might have visited their doctor less with symp-
toms of upper respiratory tract infection suggestive of
IM or doctors might have become more selective in
their use of confirmatory testing. In both cases, the fall
in test requests should have been greater than the de-
crease in positive tests. Figure 3 shows this was not the
case; the proportion of positive results decreased over
the study period.
We went on to analyse the ages and genders of tests
and diagnoses, which revealed several features of inter-
est. Figure 4 shows the characteristic adolescent peaks of
diagnoses; the female median age was 17 [IQR 15–20]
and the male median age 19 [IQR 16–22]. The femalepeak age is significantly (p < 0.0001) younger than the
male. Furthermore, more females were diagnosed with
the disease. However, the number of requests for females
was considerably greater, perhaps because overall female
consultation rates are higher than those of males. Ana-
lysis of temporal trends split by gender showed the de-
creases in both positive and negative tests were similar
for both males and females (data not shown). Further-
more, diagnostic yield falls progressively after the age of
20 and is very low over the age of 30.
Two statistical tests, Edwards’ and Roger’s tests, for
analysis of cyclical variation in tests were utilised to ex-
plore the hypothesis of seasonality in testing patterns
and test results. The peak month, amplitude and 95%
confidence intervals (CI) are displayed in Table 1 and
significance expressed as p-values, where p < 0.001 is
statistically significant, are also shown. The amplitude
varied from 10.5% to 32.4% in the statistically significant
groups. The number of positive tests was seasonal in all
patients, men and women aged 0–24 years, the age
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Figure 3 Positive / Total Monospot IM test results from 1997
to 2012.
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IM. Overall, the peak rate of positive tests was recorded
in February and trough rates in August with statistically
significant seasonal variation. This late winter peak and
summer trough pattern is replicated further after split-
ting the total number of positive tests by gender and by
age groups of 0–14 years and 15–24 years. Figure 5 pre-
sents the seasonal trend of positive tests separately for
these two age groups, with sinusoidal curves.
Discussion
We performed a survey of the number of positive and
negative IM test results in the Grampian region over
16 years, motivated by a desire to investigate seasonality.
The major change was a decrease in the number of diag-
noses over the study period. A seasonal variation was also
detected, with the disease peaking in late winter.0
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Figure 4 Number of positive and negative Monospot tests by age anThe large number of cases and consistent trend makes
us confident that our main finding is not a result of ran-
dom variation. We also controlled for possible decreases
in the number of susceptible individuals by analysing
data about the size and age structure of the Grampian
population over the study period so making changes in
the denominator population an unlikely cause of the re-
duction in the IM rate. We are confident that we captured
essentially all the diagnostic tests performed in our study
area; all the General Practices in Grampian have a collec-
tion every weekday with delivery to a central laboratory.
However, it is important to highlight that this was not set
up as a formal incidence study on primary infection with
EBV. In addition, changes in ‘diagnostic behaviour’ are
difficult to control for. For instance, it is possible that
the decrease may have arisen from either patients with
IM seeking medical advice less often or doctors becom-
ing less likely to request confirmatory tests over the last
15 years. All IM tests are provided without charge to
both General Practitioners and hospital physicians, so
there was no financial incentive to change behaviour.
More objectively, other haematological blood tests from
General Practitioners in Grampian have increased 2.2
fold over this time period.
The above findings are in contrast with the previous
data from our study area, although there were significant
methodological differences between the studies and the
1960s study also included patients for the Northern
Islands of Scotland. Over the period of 1960–1969, 8828
cases were investigated and 1258 seropositive cases were
found. The incidence increased from 11.1 to 44.3 cases
per 100 000 and there was no significant seasonal vari-
ation in seropositive or seronegative cases [25]. Due to a
number of different factors, of which the rise of the oile negative tests
e positive tests
egative postive tests
ositive tests
 / years
40 50 60 70 80
d gender.
Table 1 Peak month, Amplitude and Significance of tests for seasonal trends in total and positive Monospot test
results by age and gender
Positive test results
Numbers analysed Peak month Amplitude (%) Crude 95% CI* Edwards’ & Roger’s P
All tests
0-14 1150 March 31.3 31.0-31.5 <0.0001
15-24 6119 February 14.3 14.2-14.3 <0.0001
25-44 1156 March 1.9 1.7-2.1 0.9
>45 222 August 18.3 17.0-19.6 0.3
All ages 8647 February 13.8 13.8-14 <0.0001
Female
0-14 691 March 32.4 32.0-32.8 <0.0001
15-24 3300 February 16.2 16.1-16.3 <0.0001
25-44 554 February 8.1 7.6-8.6 0.1
>45 101 April 29.1 26.3-31.8 0.3
All ages 4646 February 16.6 16.6-17.0 <0.0001
Male
0-14 459 March 29.9 29.3-30.5 <0.0001
15-24 2819 February 11.9 11.8-12.0 <0.0001
25-44 602 July 4.4 3.9-4.9 0.6
>45 121 August 20.3 18.1-22.7 0.2
All ages 4001 February 10.5 10.5-10.6 <0.0001
Total tests performed
Numbers analysed Peak month Amplitude (%) Crude 95% CI* Edwards’ & Roger’s P
All tests
0-14 9884 February 34.5 34.4-34.5 <0.0001
15-24 30663 February 12.2 12.2-12.2 <0.0001
25-44 17615 April 12.9 12.9-12.9 <0.0001
>45 4066 March 13.0 12.9-13.1 <0.0001
All ages 62228 February 13.8 13.8-13.8 <0.0001
Female
0-14 5565 February 32.1 32.0-32.2 <0.0001
15-24 18873 February 13.1 13.1-13.1 <0.0001
25-44 10936 March 16.6 16.5-16.6 <0.0001
>45 2449 March 17.0 16.9-17.1 <0.0001
All ages 37823 February 14.4 14.4-14.4 <0.0001
Male
0-14 4319 February 37.6 37.5-37.7 <0.0001
15-24 11790 February 10.8 10.8-10.9 <0.0001
25-44 6679 April 6.9 6.9-7.0 0.009
>45 1617 March 7.5 7.4-7.7 0.1
All ages 24405 February 12.8 12.8-12.9 <0.0001
*CI: 95% Confidence intervals.
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structure has also changed over time. Caution should
therefore be used when comparing these studies.Further evidence for variation in the prevalence of IM
comes from other studies. In a survey of British General
Practices incorporating a similar sized denominator
Figure 5 Seasonality of positive Monospot tests in age groups
0–14 and 15–24 years.
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http://www.biomedcentral.com/1471-2334/14/151population of 600 000, Morris and Edmunds [32] de-
scribed a reduction in annual General Practitioner con-
sultation rates for IM from 150–200 per 100 000 in
1970 to ~100 per 100 000 in 1999, with the decrease
more marked towards the end of this period. Hospital
admission data for which IM was listed as the primary
diagnosis between 1997 and 2009 in our area showed
decreasing numbers from 84 to 44 per year from 1997
to 1999, since when the number has remained stable
(data not shown). This decline in the number of admis-
sions is similar in magnitude to the decline in numbers
of positive heterophile antibody results over the study
period and contrasts with the report by Morris and
Edmonds, where the number of admissions rose despite
a fall in the number of test results. In a fourteen year
surveillance study from France, Tattevin et al. described
a significant increase in the annual incidence of sever
Epstein-Barr virus related IM between 2002 and 2004.
They reported on patients requiring admission to hospital
admitted and although the numbers were small (n = 38)
this is also in contrast to our findings [33].
We believe that the marked reduction we observed in
positive Monospot tests reflects a genuine decrease in
the number of cases of IM. IM is less common in coun-
tries with lower living standards [2] and thus presumably
there was a previous increase in the rate of IM in Western
countries as living standards improved, although it is
uncertain when this occurred. If our data are confirmed
by other surveys, it appears that this effect seems to be
reversing at a relatively rapid rate, which, if sustained,
would result in IM becoming a rare disease in approxi-
mately 15 years’ time.
This decline might be explained by a shift back to earlier
infections [34,35] or a reduction in overall infections with
EBV, so that more adults remain seronegative. However,
in 2009 the Aberdeen clinical virology laboratory detected
antibodies to EBV in 52, 71, 89, 96 and 96% of diagnosticsamples analysed in the age groups <10, 10–19, 20–29,
30–39 and >40 respectively (n = 64, 202, 183, 137, 313).
Two surveys in the nearby city of Edinburgh [3,5] showed
that 56% of 11 year olds and 75% of matriculating under-
graduates were seropositive. In a 2010 survey of pregnant
mothers in Aberdeen only 5/273 were seronegative for
EBV (unpublished data). All these data indicate that the
overall rate of infection has not declined and late infection
continues to affect about one third of individuals.
The reasons why a minority of individuals develop IM
in response to adolescent primary infection with EBV re-
main unclear, but it is seems likely that Western immune
systems have changed over the last few decades [16,17].
Environmental factors that could be driving these changes
may also have decreased susceptibility to IM.
Our analysis also demonstrated seasonal variation, with
IM being about a third more common in February than
August. An incubation period of four to six weeks implies
the peak of IM coincides with when vitamin D levels are
at their lowest. While consistent with vitamin D deficiency
being a possible contributory factor to the seasonality of
IM, other explanations are possible. For instance, IM may
be more common for the same, alternative reasons that
infections with other viruses are more common in the
winter months [36]. Splitting the seasonality analyses by
age (Table 1) reveals that the effect is strongest at young
ages, declines with increasing age and even reverses over
the age of 45. Perhaps, therefore, term times may impact
on seasonality [5]. However, to explain the increase in IM
in winter, the influx of ‘at risk’ students returning to
Grampian for winter vacation would have to greatly ex-
ceed the number of students leaving Grampian for their
vacation and we were unable to find data to confirm this.
The documentation of the seasonality of EBV infection
and specifically IM is historically inconsistent. In 1957
Newell described a seasonal pattern in IM patients older
than 15 years of age and resident in London, with the in-
cidence being higher in summer and autumn compared
to winter and spring [37]. No seasonal pattern was
recognised in a study from Rochester, Minnesota for the
period of 1950 to 1969 [38] and in another study con-
ducted during the period of 1969 to 1970 in colleges and
universities in the United States of America, no consistent
seasonal variation for IM was apparent [39]. A seasonal
pattern of EBV infection was described in 1972 in Atlanta,
Georgia. This showed two peaks in January (late winter)
and September or October (early autumn) [40]. A peak in
IM admissions to the Boston Royal Infirmary was found
in a 12 year study in the month of October [41]. Chang
et al. reported that season did not influence the rate of
EBV seroconversion in children in a nursery [42]. In a
large group, aged 18–23 from the Israeli Defence Force,
cases of IM were recorded from 1988 to 1991. However,
the peak incidence for IM was recorded during the
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sults from this body of literature are difficult to compare
due to methodological and population differences. Overall,
the hypothesis that lower levels of Vitamin D may be con-
tributing to the higher infection rate during the winter
months, an effect that may well be more marked at high
latitudes, remains a possibility, but cannot explain all these
discrepant data.
In addition to the main two observations of the study,
one other feature of our data merits comment. Our sur-
vey reported the number of positive Monospot tests was
16% higher in females. This is in keeping with findings
from a previous study in university students in Edinburgh
where a higher female EBV seropositivity prevalence rate
was found [44]. However, in our study the request rate for
females was ~55% more than males, with a correspond-
ingly higher number of negative test results. Females are
known to visit doctors more often than men and it is likely
that the number of true cases of IM may well then be
similar with respect to gender [45]. Our data suggest that
the rate of acute EBV infection seems to be declining at a
similar rate for both males and females.
At present, the most common test used for diagnosing
IM in the Grampian laboratory remains the Monospot
test (Figure 2). Literature suggests that the sensitivity of
the Monospot test can be as low as 85% and false positives
can be seen with other infections [1,46]. The alternative
is serological testing. Data on age and gender rates for
serological testing were not available for this project;
this remains a question for future research informing
this epidemiological study.
Conclusion
We performed a survey of the rates of positive Monospot
tests in Grampian, which halved over the 16 year period
and contrasts with previous increases in the study area.
This decrease might be caused by changing environmental
influences on immune responses. In addition, we found a
higher frequency of IM in late winter, in accordance with
the hypothesis that lower vitamin D levels might help
cause IM.
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